EFFECT OF CAPTOPRIL (SQ-14225) ON BLOOD-PRESSURE, PLASMA-RENIN ACTIVITY AND ANGIOTENSIN-I CONVERTING ENZYME-ACTIVITY
- 1 January 1979
- journal article
- research article
- Vol. 121 (3) , 309-+
Abstract
Patients (7) with essential hypertension and 7 patients with hypertension associated with renal artery stenosis received captopril (SQ 14225), an inhibitor of angiotensin-l converting enzyme. There was a significant reduction in mean blood pressure, from 176/113 .+-. 4/3 mm Hg during the control period to 140/90 .+-. 5/3 mm Hg during captopril administration. Five patients received captopril alone and 9 patients needed hydrochlorothiazide in addition to control their blood pressure. Captopril produced a significant increase in peripheral plasma renin activity. When measured 12 h after the administration of captopril, angiotensin l converting enzyme activity was similar to that during the control period even though the blood pressure was at or near normal. Although captopril is an effective antihypertensive agent, its action does not depend only on inhibition of plasma angiotensin l converting enzyme activity.This publication has 8 references indexed in Scilit:
- Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzymeProgress in Cardiovascular Diseases, 1978
- Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patientsProgress in Cardiovascular Diseases, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- [Radioimmunologic determination of plasma renin activity].1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- An Angiotensin Converting-Enzyme Inhibitor to Identify and Treat Vasoconstrictor and Volume Factors in Hypertensive PatientsNew England Journal of Medicine, 1974